---
title: "OpenEvidence’s $250M at $15B Is Reported, Not Company-Confirmed"
description: "Business Insider reportedly says OpenEvidence raised $250 million at a $15 billion valuation, led by Andreessen Horowitz with hospital systems participating. OpenEvidence has not announced the financing."
date: 2026-09-25T00:00:00.000Z
source: https://venturecapitaltracker.com/2026-openevidence-250m-15b-reported-a16z
---

# OpenEvidence’s $250M at $15B Is Reported, Not Company-Confirmed

> Business Insider reportedly says OpenEvidence raised $250 million at a $15 billion valuation, led by Andreessen Horowitz with hospital systems participating. OpenEvidence has not announced the financing.

**OpenEvidence reportedly raised $250 million at a $15 billion valuation**, according to reporting summarized on September 24, 2026. **Andreessen Horowitz** reportedly led, with hospital systems participating.

OpenEvidence has **not announced the financing**, and the exact stage, primary-versus-secondary split and full syndicate remain unconfirmed. This article therefore treats the transaction as a reported financing, not a company-confirmed close.

## Reported terms

| Field | Detail |
| --- | --- |
| Company | [OpenEvidence](/startup/openevidence) |
| Amount | **$250M reported** |
| Valuation | **$15B reported** |
| Reported lead | Andreessen Horowitz |
| Other reported participants | Undisclosed hospital systems |
| Stage | Not disclosed |
| Company confirmation | **None located as of Sep. 25, 2026** |

## Why the report matters

OpenEvidence operates a medical information and search product built for physicians. Its rapid adoption has made it one of the most highly valued private healthcare-AI companies.

The reported $15 billion mark would represent another step up from the **$12 billion valuation reported with a $250 million financing in January 2026**. Because both transactions use the same headline amount, readers should not merge them: the September report describes a separate new financing at a higher valuation.

Hospital systems participating as investors would be strategically meaningful. Healthcare software is often constrained by distribution, clinical trust and access to workflow data. Customer or ecosystem investors can help with those barriers, although an investment does not prove broad deployment or clinical superiority.

## What still needs confirmation

The company has not published a press release, securities filing or investor list for the reported round. It is unclear whether $250 million is entirely primary capital, whether existing shares changed hands, or whether all commitments have funded.

OpenEvidence’s usage and revenue claims also require attribution. High physician adoption does not by itself establish the accuracy of every answer, and the company continues to operate in a market with regulatory, liability and data-governance risk.

## Bottom line

The correct headline is **reported $250 million at $15 billion**. It should not be described as company-confirmed until OpenEvidence or a named investor publishes the transaction.

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 25, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.